11.07.2015 Views

Clinical Trials

Clinical Trials

Clinical Trials

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Clinical</strong> <strong>Trials</strong>: A Practical Guide ■❚❙❘instead of a factorial trial, depending on the comparison of interest. With thepresence of an interaction effect, sample size calculations will depend on the aimof the study. The possibilities are as follows:• To compare three active treatments with control and to show that anyof the treatment combinations is effective compared with the control.• To compare two active treatments with control and to show that eitherintervention is effective on its own compared with the control.• To make six pair-wise comparisons between all four groups.The final sample size for the four-arm study is determined using the same methodas above by using the largest sample size as the final trial size.How do we analyze a factorial study?It is sometimes assumed that a 2 × 2 factorial study can be analyzed by handling thefour different treatment groups separately. However, such an analysis lacks powersince it excludes a number of individuals and does not take into account thebenefits of the factorial design. On the other hand, if the study subsequently findsan unexpected interaction effect then this might be a viable approach.In general, however, the analysis should reflect the initial aim and design of thetrial when assumptions seem tenable. To incorporate the full potential of a simple2 × 2 factorial study, all individuals should be included in the analyses.ExampleThe aim of the Canadian Trial in Threatened Stroke was to investigate the use ofaspirin and sulfinpyrazone for preventing strokes and deaths [4]. The number ofstrokes or deaths in relation to the number of individuals is outlined in Table 2.These data were initially analyzed by comparing the odds of stroke or death forindividuals on aspirin and individuals not on aspirin (odds ratio 0.63; P = 0.03).The odds ratio of stroke or death for patients who received sulfinpyrazonecompared with those who did not was not significant. Thus, it was concluded thataspirin, but not sulfinpyrazone, had a protective effect against stroke and death.Treatment interactionThe underlying assumption of no treatment interaction in the analysis ofconventional factorial studies needs to be validated; it is possible to test for thepresence of an interaction by including an interaction term between treatments ina regression model, and comparing the same model without the interaction term(see Chapter 27). If the interaction term is a significant part of the model,105

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!